Ichnos Glenmark Innovation’s Post

The Future of Radiopharmaceuticals: Trends and Possibilities The recent buzz surrounding #radiopharmaceuticals , particularly Targeted Alpha-Particle Therapy (TAT), and the flurry of deals in the second half of 2023 signal an exciting road up ahead in this space. Here are some possible trends and opportunities: 1. Rise of Targeted Alpha-Particle Therapy (TAT): TAT's focus on delivering highly localized radiation directly to cancer cells while minimizing damage to healthy tissue. Advancements in alpha-emitting isotopes and antibody-conjugation strategies will likely lead to more potent and specific TAT agents. Increased clinical trials and regulatory approvals will expand access to these therapies for various cancers. 👇 Link below to a great review from Mayo Clinic and Tulane University School of Medicine on recent clinical trials of TAT's for cancer, as well as challenges that remain to be overcome. https://lnkd.in/gdQxeRCQ 2. Integration of Single-Domain Antibodies (sdAbs): sdAbs like those generated from OmnidAb (https://lnkd.in/gH8PFaqm) offer advantages like smaller size, faster clearance, and potentially higher tumor uptake compared to conventional antibodies. Their integration into radiopharmaceuticals could lead to improved imaging and therapeutic efficacy. OmnidAb is the first and only transgenic chicken host that can generate humanized single-domain antibodies, enabling greater immune recognition of highly-conserved antigens and the discovery of more diverse antibody repertoires.  Check out our webinar this Wed Jan 24th to learn more: https://lnkd.in/gssnQE-x

Really interesting approach to ADC therapeutics with conjugation to silencing mRNA.

Delpacibart Etedesiran, or AOC 1001 developed by Avidity Biosciences, Inc., receives FDA Breakthrough Therapy Designation for for Treatment of Myotonic Dystrophy Type 1. AOC 1001 consists of a mAb that binds to the transferrin receptor 1 (TfR1) conjugated with a small interfering RNA (siRNA) targeting DMPK mRNA. This allows the drug to address the underlying cause of disease by reducing DMPK mRNA, potentially alleviating the spectrum of symptoms that people with DM1 experience. The 2024 Annual Conference of our society is just around the corner, scheduled to take place in Cambridge, MA, USA on Saturday, May 11, 2024. Don’t miss out on this exceptional opportunity to network with experts from both academia and industry, register through the following link https://lnkd.in/ecmFPA4v #antibodydiscovery #immunology #oncology #annualmeeting #annualconference #antibodies #mab #mabs #mrna #aoc  #myotonicdystrophytype1 https://lnkd.in/ggytKY-a

In November 2023, we announced the commencement of the first-in-human clinical trial for ISB 2001. The trial is an open-label, multi-center study that plans to enroll 80 participants, and will encompass, both, dose escalation and expansion phases. ISB 2001 is a groundbreaking antibody, based on the TREAT™ (Trispecific Engagement by Antibodies based on the TCR) technology, and is designed to target relapsed or refractory multiple myeloma. It simultaneously targets two critical antigens: BCMA (B-cell maturation antigen) and CD38 by binding to CD3 on T-cells and co-targeting BCMA and CD38 on multiple myeloma cells.  This trispecific antibody received orphan drug designation (ODD) from the U.S. FDA in July 2023, making it IGI’s third clinical-stage asset to receive the designation.  ISB 2001 aims to overcome mechanisms of escape observed in previous treatments. Notably, it was evaluated in vitro and in vivo against multiple myeloma cell lines expressing varying levels of CD38 and BCMA. The results demonstrated potent killing efficacy, outperforming other BCMA only-targeted T-cell engagers. For more details on ISB 2001, explore our Pipeline page: https://lnkd.in/dY9j2a4D For the latest news, Mario Perro, PhD, VP - Head of Oncology Research will present the most recent in vivo and in vitro preclinical data at AACR: https://lnkd.in/dj7YE3EW #ichnosglenmarkinnovation #igi #IGInnovate #cancerresearch

Has anybody else noticed this? Cell-specific targeting of cytokines is gaining some serious momentum, with prominent companies in the space - including Bright Peak Therapeutics and Asher Bio - garnering a lot of attention (and a lot of funding to advance their therapies into the clinic). Bright Peak just closed on $90M in Series C on June 30 and Asher just closed on $55M back in May. However, I've noticed something interesting... It seems to me that the ImmunoSTAT from Cue Biopharma is far superior to most other platforms in many highly relevant aspects, but the company doesn't seem to be getting as much attention...or funding.   Here's what I mean. I was able to uncover four aspects - though, I am sure there are some I have overlooked - that make the ImmunoSTAT a superior platform. 1. The ImmunoSTAT series offers higher degree of cell type-specificity - it is able to target highly specific T cell subsets based on their TCR. Most other platforms are simply directed by antibodies to common T cell targets like CD8, or PD-1. 2. While other platforms deliver a single cytokine per compound, CUE harbors 4 full-length IL-2 molecules per compound. This promotes a higher degree of immunogenic signaling per molecule-target interaction. 3. The ImmunoSTAT platform is not simply delivering a cytokine to a specific immune cell type, it is nucleating the formation of a full-blown immune synapse (TCR engagement AND IL-2 co-stimulation), eliciting a more comprehensive immunogenic signaling cascade and potentially more robust T cell stimulation. 4. ImmunoSTAT compounds are highly modular - the stimulatory cytokine and antigen peptide can be optimized depending on disease context, empowering the expansion of a diverse pipeline. --- My name is Jeff Martin. I am the Founder and Principal Consultant at Oncoleader, LLC. We provide biotech companies in the immuno-oncology space with a wide range of services to get your message to the right people. Check out my website - linked in comments and below my profile pic - for more details --- ***This post was in no way solicited by CUE and all of the opinions here are strictly my own.

Using Sino Biological’s biotinylated SARS-CoV Spike/RBD Protein, scientists have discovered Ab08, a human monoclonal antibody with remarkable affinity for the SARS-CoV-2 receptor-binding domain (RBD). Ab08 not only neutralizes a wide range of SARS-CoV-2 variants, including Omicron, but also demonstrates therapeutic efficacy in mice. This breakthrough highlights the potential of Ab08 as a powerful tool in the ongoing battle against COVID-19. #BiotinylatedProteins #COVID19 #MonoclonalAntibodies

🌍 Attending the Oxford Global Biologics event this week in London? Learn about Bio-Techne's biosimilar antibody engineering and how advanced characterisation techniques can be applied, such as ProteinSimple Maurice icIEF and Carterra LSA platforms for equivalency studies Download the whitepaper below 👇 Alternatively, speak to our biologics experts at the Bio-Techne booth! Francesco Agueci, Ph.D. Louis Casini Saskia Hocking #biologics #biologicsuk #Biologics2024

Biosimilar antibodies are cost-effective alternatives used in disease research. Request our latest white paper to discover how Bio-Techne’s biosimilar antibodies are equivalent to the original therapeutic antibodies. Learn more about our biosimilar antibody engineering pipeline and advanced equivalency characterization techniques. Get your copy today! #BiosimilarAntibodies #AntibodyEngineering https://bit.ly/3TyUHtC

In business news,  Biolojic Design, Ltd. announced that Nektar exercised its license option to develop a program resulting from the companies’ research collaboration initiated in 2021. The antibody program selected for development (now known as NKTR-0165) is designed to modulate the tumor necrosis factor receptor type II (TNFR2) pathway in order to agonize T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. #mabs https://lnkd.in/dG4MPt5x

Happy Tuesday all! Exciting new kits launched - PBMC Cytotoxicity Assay Kits to determine CAR-T, NK, and antibody-mediated target cell death by flow cytometry (https://lnkd.in/guy5cCdn) or luciferase (https://lnkd.in/gD24G58g). Background: Lymphocyte-mediated cytotoxicity is a form of cellular immunity targeting intracellular pathogens. The most popular in vitro methods to monitor lymphocyte-mediated cytotoxicity of target cells are cell-mediated cytotoxicity assays such as ADCC (antibody-dependent cellular cytotoxicity) and TDCC (T cell-dependent cellular cytotoxicity), in which immune effector cells and target cells are co-cultured. These PBMC Cytotoxicity Assay Kits are an excellent tool to monitor your target cell toxicity following CAR-T, NK, or antibody-based immunotherapies. Reach out to me with any questions or for a quote to use these kits for your immunotherapy drug discovery! #drugdiscovery #immunotherapy #pbmc #adcc #tdcc #cancerresearch #cartcelltherapy #nk #immunooncology #scientificresearch